27 completed, 3 terminated, 2 unknown, 1 active not recruiting. 34 Phase 3, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 34 | Completed 27, Terminated 3, Unknown 2, Active not recruiting 1, Withdrawn 1 |
| Phase 2 | 7 | Completed 6, Unknown 1 |
Follow Phobia, Social: new trials by email Literature Review of Phobia, Social trials Research Report on Phobia, Social
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder VQW-765, Placebo - Social Anxiety Disorder (SAD) | Phase 3 | Active not recruiting | Vanda Pharmaceuticals | 500 | 2025-09-22 | 2026-08-17 |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety Centanafadine, Placebo - ADHD, Anxiety | Phase 3 | Completed | Otsuka Pharmaceutical Development & Commercialization, Inc. | 315 | 2025-03-26 | 2026-05-06 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder (SAD) | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 238 | 2024-09-16 | 2026-11-04 |
| Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1 225 mg BNC210, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Bionomics Limited | 370 | 2024-08-06 | 2026-05-19 |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-3) Fasedienol Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 238 | 2024-03-28 | 2026-11-03 |
| Cannabidiol for the Treatment of Anxiety Disorders: An 8-Week Pilot Study Cannabidiol (CBD) Oil Capsules, Sunflower Lecithin Oil in Capsule - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Unknown | McMaster University | 50 | 2021-12-15 | 2023-02-14 |
| Open-label Safety Trial of PH94B in Social Anxiety Disorder (SAD) PH94B - Social Anxiety Disorder | Phase 3 | Terminated | VistaGen Therapeutics, Inc. | 481 | 2021-10-01 | 2025-10-21 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge - 2 PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Terminated | VistaGen Therapeutics, Inc. | 228 | 2021-08-30 | 2025-11-24 |
| PH94B Nasal Spray for Anxiety Induced by a Public Speaking Challenge PH94B Nasal Spray, Placebo Nasal Spray - Social Anxiety Disorder | Phase 3 | Completed | VistaGen Therapeutics, Inc. | 224 | 2021-05-24 | 2025-09-12 |
| Cannabinoids for the Treatment of Anxiety Disorders: An 8-Week Pilot Study 50:2 mg(CBD:THC)/ml - Cannabinoid Oil Oral Preparation- titrated as tolerated up to a maximum 8mls twice daily (200 mg- 800 mg total dose), Placebo Oil - Generalized Anxiety Disorder, Social Anxiety Disorder | Phase 3 | Withdrawn | McMaster University | 2021-04-01 | 2021-03-24 | |
| Acute Anxiolytic Effects of Riluzole on Subjects With Social Anxiety Disorder BHV-0223, Placebo - Social Anxiety Disorder, Performance Anxiety | Phase 2 / Phase 3 | Completed | Yale University | 22 | 2017-01-01 | 2021-05-20 |
| Feasibility Study of PH94B Nasal Spray for Acute Treatment of Social Anxiety Disorder (SAD) PH94B, Placebo - Social Anxiety Disorder | Phase 3 | Completed | Pherin Pharmaceuticals, Inc. | 23 | 2014-03-01 | 2015-12-07 |
| Computerized Cognitive Behavioral Therapy for Childhood Anxiety in Community Health Centers Computerized Cognitive Behavioral Therapy, Treatment as usual - Generalized Anxiety Disorder, Social Phobia | Phase 3 | Completed | University of South Florida | 100 | 2011-08-01 | 2019-06-18 |
| Transfer of Manualized Cognitive-Behavioral Therapy (CBT) for Social Phobia Into Clinical Practice CBT-Manualized Intervention, CBT-Treatment as Usual - Social Phobia | Phase 2 / Phase 3 | Unknown | Technische Universität Dresden | 116 | 2010-09-01 | 2011-07-08 |
| Cognitive-Behavioral Treatment for Anxiety Disorders in Children With Autism Spectrum Disorders Cognitive-behavioral therapy, Treatment as Usual - Autism, Asperger's Syndrome | Phase 2 / Phase 3 | Completed | University of South Florida | 45 | 2010-04-01 | 2013-04-02 |
| Yohimbine to Enhance Cognitive Behavioral Therapy (CBT) for Social Anxiety Group Cognitive Behavioral Therapy, Yohimbine Hydrochloride, Sugar Pill - Social Anxiety Disorder | Phase 3 | Completed | Southern Methodist University | 40 | 2009-03-01 | 2013-11-11 |
| Flushing in Social Anxiety Disorder on Seroquel Seroquel, Sugar Pill - Social Anxiety Disorder | Phase 3 | Completed | START Clinic for Mood and Anxiety Disorders | 21 | 2008-10-01 | 2014-02-25 |
| A Systems Level Intervention for Unemployed Persons With Social Anxiety Disorder Cognitive Behavioral Therapy Group, Vocational Services as Usual - Social Anxiety Disorder | Phase 2 / Phase 3 | Completed | University of Michigan | 165 | 2008-04-01 | 2012-07-31 |
| Treatment of Social Phobia and Panic Disorder in Adults individual cognitive-behavioural therapy, stepped care model - Social Phobia, Panic Disorder | Phase 3 | Completed | Haukeland University Hospital | 174 | 2008-03-01 | 2016-01-26 |
| Effect of D-cycloserine Plus Cognitive Behavioral Therapy on People With Social Phobia D-cycloserine, Cognitive behavioral therapy (CBT), Placebo - Social Anxiety Disorder | Phase 3 | Completed | Boston University Charles River Campus | 169 | 2007-12-01 | 2019-02-26 |
Showing 20 of 34. Sign in to see all of them.
Anxiety Disorders (15) · Generalized Anxiety Disorder (9) · Anxiety, Separation (4) · Panic Disorder (3) · Phobic Disorders (3) · Psychological Well-Being (3) · Agoraphobia (2) · Disease (2) · Marijuana Abuse (2) · Obsessive-Compulsive Disorder (2) · Asperger Syndrome (1) · Attention Deficit Disorder with Hyperactivity (1) · Autistic Disorder (1) · Mental Disorders (1)
Mental Disorders (33) · Phobic Disorders (31) · Anxiety Disorders (19) · Neurodevelopmental Disorders (6) · Behavior (3) · Pathological Conditions, Signs and Symptoms (3) · Personal Satisfaction (3) · Chemically-Induced Disorders (2) · Pathologic Processes (2) · Substance-Related Disorders (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Autism Spectrum Disorder (1) · Child Development Disorders, Pervasive (1) · Communication Disorders (1) · Language Disorders (1)
Cognitive Behavioral Therapy (5) · Quetiapine Fumarate (3) · Sugars (3) · Therapeutics (2) · Cannabidiol (1) · Capsules (1) · Counseling (1) · Cycloserine (1) · Duloxetine Hydrochloride (1) · Exercise (1) · Fluoxetine (1) · Fluvoxamine (1) · Hypericum extract LI 160 (1) · Memantine (1) · Oils (1)
VistaGen Therapeutics, Inc. (5) · GlaxoSmithKline (2) · McMaster University (2) · University of South Florida (2) · AstraZeneca (1) · Bionomics Limited (1) · Boston University Charles River Campus (1) · Duke University (1) · Haukeland University Hospital (1) · Johns Hopkins University (1) · Karolinska Institutet (1) · Massachusetts General Hospital (1) · Modum Bad (1) · National Center for Complementary and Integrative Health (NCCIH) (1) · National Institute of Mental Health (NIMH) (1)
United States (21) · Canada (3) · Japan (2) · Norway (2) · Germany (1) · Netherlands (1) · Puerto Rico (1) · Sweden (1)
Eric A Storch, Ph.D. (2) · Michael Van Ameringen, MD, FRCPC (2) · Asle Hoffart, Dr Psychol (1) · Finn-Magnus Borge, Cand Psychol (1) · Jaakko Lappalainen, MD, PhD (1) · Jasper A. Smits, PhD (1) · Jasper Smits, Ph.D. (1) · Jonathan Davidson, M.D. (1) · Joseph Himle, PhD (1) · Juergen Hoyer, Prof. Dr. (1) · Laurence Greenhill, MD (1) · Mark H. Pollack, MD (1) · Mark Riddle, MD (1)
PMID 18030084, PMID 18974308, PMID 20013046, PMID 20051130, PMID 20206470, PMID 21391024, PMID 21483704, PMID 22122292, PMID 22320999, PMID 22647314, PMID 23357440, PMID 24129543, PMID 24237691, PMID 24260145, PMID 24417601, PMID 24477837, PMID 24565357, PMID 24610431, PMID 25461793, PMID 25721183, PMID 26081010, PMID 26366886, PMID 26708332, PMID 27561175, PMID 28735699, PMID 28956620, PMID 29877727, PMID 29960692, PMID 30906874, PMID 31471911, PMID 33705168, PMID 36479955, PMID 37861988, PMID 38217328, PMID 41773906
R01MH053703 (1), R01MH064481 (1), R01MH064726 (1), R01MH075889 (1), R01MH078308 (1), U01MH064089 (1)